GSK plc’s (GSK) HIV subsidiary, ViiV Healthcare announced that the Europe Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending marketing authorization for its new long-acting HIV regimen.ViiV Healthcare is a global specialist HIV company, majorly owned by GSK with Pfizer (PFE) and Shionogi as shareholders.ViiV Healthcare was formed by GSK and Pfizer in 2009.The CHMP recommended marketing authorization to Vocabria (cabotegravir long-a ...